Fast Track Group FTRK 深 沪
等待开盘 11-03 09:30:00 美东时间
0.4918
+0.003
+0.57%
华盛通- 最 高0.52
- 今 开0.4788
- 成交量 27.21万股
- 最 低 0.4553
- 昨 收 0.489
- 总市值 1072.74万
- 52周最高 9.69
- 市盈率 静 --
- 换手率 1.25%
- 52周最低 0.3898
- 委 比 87.49%
- 总股本 2181.25万
- 历史最高 9.69
- 量 比 0.77
- 振 幅 13.23%
- 历史最低 0.3898
- 每 手 1
- 风险率 1.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
Double-blind trial data shows increased efficacy of ATH434 at high doses, while open-label trial results confirm similar benefits in advanced MSA. ATH434 has a potential peak sales opportunity of $2.4 billion globally. Alterity's cash balance as of September 2025 is A$54.56M. The company is engaging with the FDA to advance ATH434 toward Phase 3 trials, with an End-of-Phase 2 meeting expected in mid-2026. Positive clinical outcomes and regulatory ...
10-31 11:25
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
Seres Therapeutics将于11月5日举行电话会议，讨论2025年第三季度财务结果并提供业务更新。投资者可拨打800-715-9871（美国）或646-307-1963（国际）参与，会议ID为8471287。网络直播可通过公司网站www.serestherapeutics.com访问，会议还将提供21天的录音回放。Seres专注于开发创新活菌生物治疗，已成功开发并批准首款FDA批准的口服微生物组疗法VOWST，现正在开发SER-155，该产品已获突破性疗法指定，用于减少造血干细胞移植后血液感染和移植物抗宿主病风险。公司计划在多种高危患者群体中测试SER-155及其他活菌生物治疗候选药物。
10-30 11:00
Xuanzhu Biopharmaceutical’s NG-350A Receives FDA Fast Track Designation
Xuanzhu Biopharmaceutical Co., Ltd. Class H ( ($HK:2575) ) just unveiled an upd...
10-28 16:40
Alphamab Oncology’s JSKN003 Gains U.S. FDA Fast Track Designation
An update from Alphamab Oncology ( ($HK:9966) ) is now available. Alphamab Onco...
10-27 22:08
Lilly to Acquire Adverum Biotechnologies
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition ali...
10-24 20:30
BioAtla Presents Ozuriftamab Vedotin Clinical Data Targeting ROR2 In HPV+ Head & Neck Cancer at IPVS Conference 2025
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced
10-23 20:17
药捷安康-B盘中涨超25% 于2025年ESMO年会上公布替恩戈替尼研究数据并获口头报告
药捷安康-B（02617）早盘一度涨超25%，高见217港元，截至发稿，股价上涨19.35%，报199.20港元，成交额7.86亿港元。 据药捷安康官微...
10-22 10:04
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, Oct. 21, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Conventional small molecule approaches hav...
10-21 21:20
香港金融科技周 x StartmeupHK创业节2025：共庆十载创新同行 规模空前环球嘉宾云集
投资推广署今日（十月十七日）公布香港金融科技周 x StartmeupHK创业节2025的详情。今年两大旗舰盛事踏入十周年庆典，将于十一月三日至七日联合举行，打...
10-20 15:45
